Document is current
Any future updates will be listed below
-
Authors
Huang, Chaoli
Wu, Zifeng
Wang, Di
Qu, Youge
Zhang, Jichun https://orcid.org/0000-0001-6035-6867
Jiang, Riyue
Xu, Xiangqing
Xu, Xiangyang
Wang, Yuanyuan
Liu, Hanyu
He, Teng
Liu, Cunming https://orcid.org/0000-0003-4935-3758
Chen, Guiquan
Yang, Jian-jun https://orcid.org/0000-0001-6785-9627
Hashimoto, Kenji https://orcid.org/0000-0002-8892-0439
Yang, Chun https://orcid.org/0000-0003-1540-4385
- License Information
-
More Information
Article History
Received: 24 May 2023
Revised: 2 October 2023
Accepted: 3 October 2023
First Online: 17 October 2023
Competing interests
: CY has received research support from Nhwa. KH is the inventor of filed patent applications on “The use of <i>R</i>-Ketamine in the treatment of psychiatric diseases”, “(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “<i>R</i>-Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, and “<i>R</i>-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. KH has also received speakers’ honoraria, consultant fee, or research support from Abbott, Meiji Seika Pharma, Seikagaku Corporation, Sumitomo Pharma, Taisho, Otsuka, Murakami Farm and Perception Neuroscience. Other authors declare no conflict of interest.
